Brief: Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering To Refinance 2029 Convertible Notes
07/05/2026 03:28
May 6 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE PRICES UPSIZED $475.0 MILLION CONVERTIBLE SENIOR NOTES OFFERING TO REFINANCE 2029 CONVERTIBLE NOTES TRAVERE THERAPEUTICS INC - PRICES $475 MILLION 0.50% CONVERTIBLE SENIOR NOTES DUE 2032; CLOSING EXPECTED MAY 11, 2026 Source text: ID:nBw7mV12Ta Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule